Gothenburg, Sweden — Denator AB announced today that the company has been awarded funding from the Vinnova Forska&Väx programme. Denator will receive 500 000 SEK for a pre-study for stabilization of clinical samples for improving correct diagnosis.

The programme Forska&Väx will distribute 70 MSEK to 64 small and medium-sized companies as financing for their R&D efforts. Over 280 companies applied for an amount of 406 MSEK. All projects have been assessed by carefully selected independent technical experts and independent evaluation panel.

The project will focus on stabilization of clinically relevant phosphorylations for immunohistochemistry analysis. Phosphorylations play a key role in several diseases such as cancer and neurodegenerative diseases. To correctly determine the state or level of a specific phosphorylation can be crucial to understand its role in the course of events for a certain disease. Partners in the project include key researchers at Karolinska Institute and a leading pan-European actor within clinical diagnostics.

Dr Mats Borén, Head of Development at Denator and Project Leader of the Forska&Väx project, says: “The ability to stabilize tissue samples will enable the use of new labile biomarkers in the clinic, thereby facilitating faster and more accurate disease diagnosis.”

Olof Sköd, CEO of Denator, says: “This project will allow us to continue verifying our proprietary technology for stabilization of biological samples. This will lead to further increase in the market potential for the technology and open up large market segments within diagnostics and healthcare”

Denator’s first commercial system for tissue stabilization was launched at the HUPO meeting in Amsterdam in August, 2008.

About Denator

Denator develops and markets products that stabilize biological tissues and fluids from the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. In proteomic and peptidomic investigations, enhanced data quality increases the reliability of data interpretation and can reveal novel proteins and peptides that would be lost or undetectable when using conventional preparation techniques. Based upon the company’s proprietary heat-inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation instantly and maintain the stability of sample components throughout the analytical workflow. Established in 2004, Denator is headquartered at the Biotech Center in Gothenburg, Sweden. For more information visit: www.denator.com